PPARG and metabolic syndrome: Considering the large number of diabetes patients and the popularity of PPARγ agonists (Rosiglitazone, Pioglitazone) class anti-diabetes drugs, elevated cardiac FABP4 expressions may be quite common among metabolic syndromes patients.